RDY Quote, Financials, Valuation and Earnings

Concord Medical Services Holdings has a net margin of 18.74% compared to Dr Reddy's Laboratories's net margin of --. Dr Reddy's Laboratories's return on equity of 18.27% beat Concord Medical Services Holdings's return on equity of -19.78%.

Dr Reddy's Laboratories has a consensus price target of $14.97, signalling upside risk potential of 1.88%. On the other hand Concord Medical Services Holdings has an analysts' consensus of -- which suggests that it could grow by 122.22%. Given that Concord Medical Services Holdings has higher upside potential than Dr Reddy's Laboratories, analysts believe Concord Medical Services Holdings is more attractive than Dr Reddy's Laboratories.

Dr Reddy's Laboratories has a beta of 0.333, which suggesting that the stock is 66.713% less volatile than S&P 500. In comparison Concord Medical Services Holdings has a beta of -0.899, suggesting its less volatile than the S&P 500 by 189.948%.

Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.65%. Concord Medical Services Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr Reddy's Laboratories pays 11.78% of its earnings as a dividend. Concord Medical Services Holdings pays out -- of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr Reddy's Laboratories quarterly revenues are $982M, which are larger than Concord Medical Services Holdings quarterly revenues of --. Dr Reddy's Laboratories's net income of $184M is higher than Concord Medical Services Holdings's net income of --. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 22.36x while Concord Medical Services Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.18x versus 0.44x for Concord Medical Services Holdings. Usually stocks with elevated PS ratios are considered overvalued.

HDFC Bank has a net margin of 18.74% compared to Dr Reddy's Laboratories's net margin of 25.7%. Dr Reddy's Laboratories's return on equity of 18.27% beat HDFC Bank's return on equity of 12.02%.

Dr Reddy's Laboratories has a consensus price target of $14.97, signalling upside risk potential of 1.88%. On the other hand HDFC Bank has an analysts' consensus of $86.23 which suggests that it could grow by 13.25%. Given that HDFC Bank has higher upside potential than Dr Reddy's Laboratories, analysts believe HDFC Bank is more attractive than Dr Reddy's Laboratories.

Dr Reddy's Laboratories has a beta of 0.333, which suggesting that the stock is 66.713% less volatile than S&P 500. In comparison HDFC Bank has a beta of 0.639, suggesting its less volatile than the S&P 500 by 36.068%.

Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.65%. HDFC Bank offers a yield of 1.93% to investors and pays a quarterly dividend of $0.78 per share. Dr Reddy's Laboratories pays 11.78% of its earnings as a dividend. HDFC Bank pays out 23.47% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr Reddy's Laboratories quarterly revenues are $982M, which are smaller than HDFC Bank quarterly revenues of $8.5B. Dr Reddy's Laboratories's net income of $184M is lower than HDFC Bank's net income of $2.2B. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 22.36x while HDFC Bank's PE ratio is 23.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.18x versus 8.76x for HDFC Bank. Usually stocks with elevated PS ratios are considered overvalued.

SS Innovations International has a net margin of 18.74% compared to Dr Reddy's Laboratories's net margin of -110.95%. Dr Reddy's Laboratories's return on equity of 18.27% beat SS Innovations International's return on equity of -76.16%.

Dr Reddy's Laboratories has a consensus price target of $14.97, signalling upside risk potential of 1.88%. On the other hand SS Innovations International has an analysts' consensus of -- which suggests that it could fall by --. Given that Dr Reddy's Laboratories has higher upside potential than SS Innovations International, analysts believe Dr Reddy's Laboratories is more attractive than SS Innovations International.

Dr Reddy's Laboratories has a beta of 0.333, which suggesting that the stock is 66.713% less volatile than S&P 500. In comparison SS Innovations International has a beta of -68.829, suggesting its less volatile than the S&P 500 by 6982.93%.

Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.65%. SS Innovations International offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr Reddy's Laboratories pays 11.78% of its earnings as a dividend. SS Innovations International pays out -- of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr Reddy's Laboratories quarterly revenues are $982M, which are larger than SS Innovations International quarterly revenues of $5.1M. Dr Reddy's Laboratories's net income of $184M is higher than SS Innovations International's net income of -$5.7M. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 22.36x while SS Innovations International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.18x versus 68.77x for SS Innovations International. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab has a net margin of 18.74% compared to Dr Reddy's Laboratories's net margin of -45.49%. Dr Reddy's Laboratories's return on equity of 18.27% beat Zai Lab's return on equity of -33.29%.

Dr Reddy's Laboratories has a consensus price target of $14.97, signalling upside risk potential of 1.88%. On the other hand Zai Lab has an analysts' consensus of $56.38 which suggests that it could grow by 56.58%. Given that Zai Lab has higher upside potential than Dr Reddy's Laboratories, analysts believe Zai Lab is more attractive than Dr Reddy's Laboratories.

Dr Reddy's Laboratories has a beta of 0.333, which suggesting that the stock is 66.713% less volatile than S&P 500. In comparison Zai Lab has a beta of 0.989, suggesting its less volatile than the S&P 500 by 1.125%.

Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.65%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr Reddy's Laboratories pays 11.78% of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr Reddy's Laboratories quarterly revenues are $982M, which are larger than Zai Lab quarterly revenues of $106.5M. Dr Reddy's Laboratories's net income of $184M is higher than Zai Lab's net income of -$48.4M. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 22.36x while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.18x versus 8.75x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.